Which generation of targeted drug is entrectinib?

Entrectinib is a third-generation targeted drug. Entrectinib was released in20198Obtained FDA approval for the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors. Entrectinib treats a certain type of non-small cell lung cancer in adults that has spread to other parts of the body. Entrectinib is also approved to treat pediatric and adult patients with NTRK fusion-positive, recurrent or advanced solid tumors.

Entrectinibis a tyrosine kinase inhibitor that acts on several receptors. As an ATP competitor, it inhibits tropomyosin receptor tyrosine kinase (TRK) TRKA, span>TRKB, TRKC, and the proto-oncogenes tyrosine-protein kinaseROS1 and anaplastic lymphoma kinase (ALK).

Entrectinib belongs to the kinase inhibitor class of drugs. Entrectinib works by blocking the activity of abnormal proteins, which are signals for cancer cell reproduction. This helps prevent or slow down the spread of cancer cells. The recommended dose of entrectinib is 600 mgorally once daily. If the patient misses a dose less than 12 hours, take the missed dose as soon as possible after remembering and then take the next dose at the scheduled time. However, if a dose is missed by more than 12 hours, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the missed dose. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0